title: Malaria protection in Sierra Leone during the Ebola outbreak 2014/15; The UK military experience with malaria chemoprophylaxis Sep 14-Feb 15.
abstract: BACKGROUND
  The UK deployed a task force to Sierra Leone to assist in ending the 2014/15 Ebola outbreak. Malaria protection was based on existing Defence Policy which saw a wide range of bite prevention measures deployed. Atovaquone/Proguanil ("A/P"), Doxycycline ("D") and Mefloquine ("M") were the chemoprophylactic medications that were prescribed. A survey was undertaken to audit the Adverse Effect (AE) burden experienced by the population.
  
  
  METHODS
  A questionnaire based survey was administered that sought information on individuals' experiences with malaria chemoprophylaxis.
  
  
  RESULTS
  337 personnel were eligible to take part and 151 (46.3%) individuals returned questionnaires. The reported AE rates for the three drugs were "A/P" 28% of the respondents, "D" 25% and "M" 23.1%. 24 individuals (15.9%) reported 1 AE while 34 (22.5%) reported multiple AEs. Eight (5.3%) individuals changed medication (Five "A/P", two "M" and one "D") because of unacceptable AE but no significant neuro/psychological conditions were reported. The malaria attack rate for the deployed population was 0.4 cases per thousand person weeks which is very low when compared to other military deployments to the West African Area.
  
  
  CONCLUSIONS
  UK Defence policy is effective in the way it balances the risk of malaria with that of AE due to chemoprophylaxis. "M" remains an acceptable chemoprophylactic agent for a section of the population.
authors.affiliation: HQ Combined Joint Inter Agency Task Force, Operation GRITROCK, British Forces Post Office 609, United Kingdom. Electronic address: Jjhtinsl2014@gmail.com.
authors.forename: Jeremy
authors.initials: J
authors.lastname: Tuck
authors.affiliation: HQ Combined Joint Inter Agency Task Force, Operation GRITROCK, British Forces Post Office 609, United Kingdom.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Williams
mesh_terms: D000328:Adult; D000962:Antimalarials / Q000008:administration & dosage / Q000009:adverse effects*; D053626:Atovaquone / Q000008:administration & dosage / Q000009:adverse effects; D018890:Chemoprevention / Q000009:adverse effects*; D004196:Disease Outbreaks / Q000517:prevention & control / Q000706:statistics & numerical data; D004318:Doxycycline / Q000008:administration & dosage / Q000009:adverse effects; D004338:Drug Combinations; D019142:Hemorrhagic Fever, Ebola / Q000453:epidemiology* / Q000821:virology; D006801:Humans; D008288:Malaria / Q000453:epidemiology / Q000469:parasitology / Q000517:prevention & control*; D015767:Mefloquine / Q000008:administration & dosage / Q000009:adverse effects; D008889:Military Personnel; D002727:Proguanil / Q000008:administration & dosage / Q000009:adverse effects; D012807:Sierra Leone / Q000453:epidemiology; D011795:Surveys and Questionnaires; D014195:Travel; D006113:United Kingdom
chemical_list: D000962:Antimalarials; D004338:Drug Combinations; C109496:atovaquone, proguanil drug combination; D004318:Doxycycline; D002727:Proguanil; D015767:Mefloquine; D053626:Atovaquone
keywords: Adverse; Audit; Chemoprophylaxis; Events; Malaria